Publications by authors named "Barbara S Schug"

Objectives: To investigate the effect of different oral dosages of levonorgestrel (LNG) on ovarian activity and to identify the lowest dosage at which no ovulation occurred. Secondary objectives were to assess return of ovulation after stopping treatment, bleeding pattern, pharmacokinetic (PK) parameters and safety and tolerability.

Study Design: A parallel-group study with adaptive design was performed in 90 healthy women with proven ovulatory cycles.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to find the lowest effective dose of trimegestone (TMG) using a vaginal ring for inhibiting ovulation among 80 healthy women over 28 days.
  • Results showed that the 94 µg/day dose was effective in preventing ovulation, while higher doses had no ovulations and provided better ovarian suppression.
  • The TMG vaginal ring was found to be safe and well-tolerated, suggesting it could be a viable future option for progestogen-only contraception with the convenience of monthly insertion.
View Article and Find Full Text PDF
Article Synopsis
  • The Global Bioequivalence Harmonization Initiative (GBHI) was created to align regulatory standards for bioequivalence assessments globally, starting in 2015 through conferences organized by EUFEPS and AAPS.
  • The 2nd GBHI conference in 2016 focused on key topics like prodrugs, scaling procedures, and excluding pharmacokinetic data from BE assessments.
  • Discussions at the conference fostered a better understanding among pharmaceutical scientists and helped harmonize regulations related to the approval of multisource drug products.
View Article and Find Full Text PDF

Fentanyl is an opioid initially developed for parenteral administration. While oral administration is not an option due to a high first-pass metabolism, its high potency and lipophilicity have made a number of new routes of administration feasible. The transdermal therapeutic system offers an excellent option for long-term treatment of cancer and chronic pain, achieving stable plasma concentrations over the treatment period.

View Article and Find Full Text PDF

An acute pharyngitis is characterised by mild to severe sore throat mostly accompanied by inflammation, throat pain, pain on swallowing, and burning. This randomised, double-blind, placebo-controlled phase III study was conducted for comparison of the efficacy and safety of a newly developed lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide, CAS 137-58-6) 8 mg lozenge formulation (Trachisan Halsschmerztabletten) for the treatment of acute sore throat not necessarily to be treated with antibiotics. 240 patients of both genders were enrolled.

View Article and Find Full Text PDF

Proton pump inhibitors are used extensively for the treatment of gastric acid-related disorders because they produce a greater degree and longer duration of gastric acid suppression and, thus, better healing rates, than histamine H(2) receptor antagonists. The need for long-term treatment of these disorders raises the potential for clinically significant drug interactions in patients receiving proton pump inhibitors and other medications. Therefore, it is important to understand the mechanisms for drug interactions in this setting.

View Article and Find Full Text PDF

The neurotropic-musculotropic spasmolytic agent denaverine hydrochloride is used mainly in the treatment of smooth muscle spasms of the gastrointestinal and urogenital tract. Despite its commercial availability as a solution for intravenous or intramuscular administration (ampoule) and as a suppository formulation, no pharmacokinetic data in man was available to date. Therefore, the objectives of this clinical trial were to determine the basic pharmacokinetic parameters of denaverine after intravenous administration, to assess the feasibility of using the oral route of administration and to characterise the bioavailability of the suppository formulation.

View Article and Find Full Text PDF

The objective of this study was a comparative investigation of the influence of concomitant food intake on the bioavailability of two nifedipine-containing controlled-release formulations. Adalat OROS and CORAL were compared in a randomised, non-blind, four-way crossover design in 24 healthy, male subjects after single dose administration following a high fat American breakfast or an overnight fast of 12 h, respectively. Plasma samples were withdrawn until 48 h post-dose.

View Article and Find Full Text PDF